Reynolds E H, Shorvon S D
Nouv Presse Med. 1981 Dec 12;10(45):3717-9.
Although anticonvulsant polytherapy has traditionally been used on a large scale in epilepsy, there is little evidence that it has advantages over monotherapy. Furthermore, it leads to problems of chronic toxicity, drug interactions, failure to evaluate individual drugs, and sometimes exacerbation of seizures. In many cases polytherapy could be avoided by more careful monitoring and supervision of patient's compliance. Studies in new, previously untreated patients suggest that there is considerable potential for monotherapy. In chronic patients on polytherapy, there may be opportunities for careful rationalization to two or even one drug, with subsequent reduction of chronic toxicity and sometimes improvement in seizure control. Reduction of the number of drugs, however, may be impossible or hazardous owing to withdrawal seizures. It is easier to avoid polytherapy than to reduce it.
尽管传统上抗惊厥药物联合治疗在癫痫治疗中被广泛应用,但几乎没有证据表明它比单一疗法更具优势。此外,它会导致慢性毒性、药物相互作用、无法评估单一药物效果以及有时会使癫痫发作加剧等问题。在许多情况下,通过更密切地监测和监督患者的依从性,可以避免联合治疗。对新的、未经治疗的患者进行的研究表明,单一疗法具有很大的潜力。对于接受联合治疗的慢性病患者,有可能谨慎地将药物合理调整为两种甚至一种,从而降低慢性毒性,有时还能改善癫痫控制情况。然而,由于撤药发作,减少药物数量可能是不可能的或有风险的。避免联合治疗比减少联合治疗更容易。